Merus Labs International (MSL-T) Stock Predictions - Stockchase
WATCH LIST
68
Merus Labs International (MSL-T)

ON STOCKCHASE SINCE Jul 2013

Acquired July 2017

other services

Merus Labs International

MSL-T

20 watching          
Join the Discussion

Merus Labs International (MSL-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about MSL-T



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK

(A Top Pick March 29/16. Down 10%.) This is being taken over by an Italian private pharmaceutical company.

other services
0 0 0 0 0
0 comments

(A Top Pick March 29/16. Down 10%.) This is being taken over by an Italian private pharmaceutical company.

other services
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$1.640
Owned Owned
No

SELL

Sold his holdings at around $2 about 1.5 years ago. The whole sector was extremely hot, and then they all came down at the same time. This company hasn’t hit any of its targets. Has stayed away from this whole sector because there has been too much regulatory stuff. If you own, this might be a chance to get out.

other services
0 0 0 0 0
0 comments

Sold his holdings at around $2 about 1.5 years ago. The whole sector was extremely hot, and then they all came down at the same time. This company hasn’t hit any of its targets. Has stayed away from this whole sector because there has been too much regulatory stuff. If you own, this might be a chance to get out.

other services
0 0 0 0 0
0 comments
Peter Imhof

Vice Presi, AGF Investments Inc...

Price Price
$1.140
Owned Owned
No

BUY on WEAKNESS

We have a downtrend in place.  It had to hold the $1.40 level and which it did for almost 2 years and then broke it.  This is a lower risk place to come in here.  It is starting to base here again.  You might get a nice upside breakout move here. 

other services
0 0 0 0 0
0 comments

We have a downtrend in place.  It had to hold the $1.40 level and which it did for almost 2 years and then broke it.  This is a lower risk place to come in here.  It is starting to base here again.  You might get a nice upside breakout move here. 

other services
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$1.140
Owned Owned
Unknown

COMMENT

This entire space has been pretty difficult in the last year. This has been beaten up fairly hard. In his ranking system, he looks at things both fundamentally and technically. He is not seeing a lot from an earnings growth rate, and at the same time he is not seen too much strength technically. He is really not looking at this one. He would have to see a quarter or 2 of cash flow and earnings growth before looking at it.

other services
0 0 0 0 0
0 comments

This entire space has been pretty difficult in the last year. This has been beaten up fairly hard. In his ranking system, he looks at things both fundamentally and technically. He is not seeing a lot from an earnings growth rate, and at the same time he is not seen too much strength technically. He is really not looking at this one. He would have to see a quarter or 2 of cash flow and earnings growth before looking at it.

other services
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$1.180
Owned Owned
No

TOP PICK

This has been a Top Pick in the past, and he has been wrong, but with the end of tax loss selling there should be a change. They are getting the benefit of a technology transfer for manufacturing of one of their main drugs, Sintrom, from the US in US$ costs into Europe in Euro costs. That is going to take place over the next 2-3 quarters and will save them about $8 million a year. They can reinvest those savings. Their next targeted acquisitions are for drugs with an organic growth profile, something they have lacked in the past. Trading at 3X cash flow, and their closest competitor trades at 10X cash flow. There has been recent insider buying by both the CEO and a couple of board members. (Analysts’ price target is $1.84.)

other services
0 0 0 0 0
0 comments

This has been a Top Pick in the past, and he has been wrong, but with the end of tax loss selling there should be a change. They are getting the benefit of a technology transfer for manufacturing of one of their main drugs, Sintrom, from the US in US$ costs into Europe in Euro costs. That is going to take place over the next 2-3 quarters and will save them about $8 million a year. They can reinvest those savings. Their next targeted acquisitions are for drugs with an organic growth profile, something they have lacked in the past. Trading at 3X cash flow, and their closest competitor trades at 10X cash flow. There has been recent insider buying by both the CEO and a couple of board members. (Analysts’ price target is $1.84.)

other services
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$1.080
Owned Owned
Yes

DON'T BUY

There has been no good news in the last couple of quarters.  He got out when he saw no growth coming through.  Regulatory things going on in Europe have hurt them.  This is not one of the top twenty names you want to own.

other services
0 0 0 0 0
0 comments

There has been no good news in the last couple of quarters.  He got out when he saw no growth coming through.  Regulatory things going on in Europe have hurt them.  This is not one of the top twenty names you want to own.

other services
0 0 0 0 0
0 comments
Peter Imhof

Vice Presi, AGF Investments Inc...

Price Price
$0.960
Owned Owned
No

TOP PICK

They did not take on all the debt of some others.  It is in Europe.  When US drugs come off patent, it is a patent cliff.  In Europe it is different.  It tends to be about 30-40% because it is more highly regulated to begin with.  Their earnings are more stable.  He likes the management team who have been buying stock recently.  They changed from just buying legacy drugs to buying growth drugs.  He thinks this growth strategy will cause a re-rating of the stock.

other services
0 0 0 0 0
0 comments

They did not take on all the debt of some others.  It is in Europe.  When US drugs come off patent, it is a patent cliff.  In Europe it is different.  It tends to be about 30-40% because it is more highly regulated to begin with.  Their earnings are more stable.  He likes the management team who have been buying stock recently.  They changed from just buying legacy drugs to buying growth drugs.  He thinks this growth strategy will cause a re-rating of the stock.

other services
0 0 0 0 0
0 comments
James Hodgins

Chief Inve, Curvature Hedge Stra...

Price Price
$1.260
Owned Owned
Yes

SELL
Merus Labs International(MSL-T) 

September 16, 2016

This has gone nowhere in 5 years. There is an overhead supply in 2014-2015, and as a result these investors are caught Long, and are selling and pushing it down. He doesn’t see any strong buying here, and as a result would not recommend holding. It is making lower highs and lower lows.

other services
0 0 0 0 0
0 comments

This has gone nowhere in 5 years. There is an overhead supply in 2014-2015, and as a result these investors are caught Long, and are selling and pushing it down. He doesn’t see any strong buying here, and as a result would not recommend holding. It is making lower highs and lower lows.

other services
0 0 0 0 0
0 comments
William Chin

Portfolio , Caldwell Investment ...

Price Price
$1.330
Owned Owned
Unknown

COMMENT

(Market Call Minute.) This buys specialty drugs, which is a tougher environment to do that in the post-Valeant and Concordia world.

other services
0 0 0 0 0
0 comments

(Market Call Minute.) This buys specialty drugs, which is a tougher environment to do that in the post-Valeant and Concordia world.

other services
0 0 0 0 0
0 comments
James Rife

Head of Ca, Canalyst Financial M...

Price Price
$1.640
Owned Owned
Unknown

PAST TOP PICK

(A Top Pick July 27/15. Down 45.05%.) This is by far the cheapest Canadian health care stock. They have business in Europe, not in the US or Canada, but the debt is hedged. They announced that the change in the EBITDA would be less than 1%. He is holding on.

other services
0 0 0 0 0
0 comments

(A Top Pick July 27/15. Down 45.05%.) This is by far the cheapest Canadian health care stock. They have business in Europe, not in the US or Canada, but the debt is hedged. They announced that the change in the EBITDA would be less than 1%. He is holding on.

other services
0 0 0 0 0
0 comments
Bruce Campbell

President, Campbell and Lee Inv...

Price Price
$1.650
Owned Owned
Yes

BUY

They have been on his radar because they meet his target.  He would like to see it break above $2.25.  It is probably a very good company, though.

other services
0 0 0 0 0
0 comments

They have been on his radar because they meet his target.  He would like to see it break above $2.25.  It is probably a very good company, though.

other services
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$1.690
Owned Owned
No

WATCH

It has a lot of exposure in Europe and so has been weak recently.  You would have expected the market to get behind their recent acquisition, but there is no momentum behind the healthcare names.  He would like to see it improve just a little bit and if it built this base and started to move up he would look at it.

other services
0 0 0 0 0
0 comments

It has a lot of exposure in Europe and so has been weak recently.  You would have expected the market to get behind their recent acquisition, but there is no momentum behind the healthcare names.  He would like to see it improve just a little bit and if it built this base and started to move up he would look at it.

other services
0 0 0 0 0
0 comments
Bruce Campbell

President , Stone Castle Investm...

Price Price
$1.650
Owned Owned
No

HOLD

Buys older legacy drugs that big Pharma companies don’t want anymore. Generally they are free cash flowing drugs. Mostly in Europe. The stock has been extremely weak, but he is not seeing any good reason why the stock has dropped from $2 down to $1.65. Fundamentals are still intact. Last quarter was okay.

other services
0 0 0 0 0
0 comments

Buys older legacy drugs that big Pharma companies don’t want anymore. Generally they are free cash flowing drugs. Mostly in Europe. The stock has been extremely weak, but he is not seeing any good reason why the stock has dropped from $2 down to $1.65. Fundamentals are still intact. Last quarter was okay.

other services
0 0 0 0 0
0 comments
James Telfser

Partner & , Aventine Management ...

Price Price
$1.640
Owned Owned
Yes

PAST TOP PICK

(A Top Pick June 1/15. Down 49.05%.) It was caught up in the Valeant downdraft for the group. This is non-US; it is all Canada or Europe. Very cheap. Made a couple of acquisitions. Doesn’t have a stretched balance sheet. Hasn’t bought drugs that have had price increases as the main way of growing revenue. A Hold.

other services
0 0 0 0 0
0 comments

(A Top Pick June 1/15. Down 49.05%.) It was caught up in the Valeant downdraft for the group. This is non-US; it is all Canada or Europe. Very cheap. Made a couple of acquisitions. Doesn’t have a stretched balance sheet. Hasn’t bought drugs that have had price increases as the main way of growing revenue. A Hold.

other services
0 0 0 0 0
0 comments
Bruce Campbell

President, Campbell and Lee Inv...

Price Price
$1.600
Owned Owned
Yes

WATCH

Greatly improved after the change in management.  They had to add on new product lines for sale in the market place.  The chart suggests that it is sloping up a little bit.  He continues to life in hope as he has done for more than a year.

other services
0 0 0 0 0
0 comments

Greatly improved after the change in management.  They had to add on new product lines for sale in the market place.  The chart suggests that it is sloping up a little bit.  He continues to life in hope as he has done for more than a year.

other services
0 0 0 0 0
0 comments
Michael Smedley

Exec VP & , Morgan Meighan & Ass...

Price Price
$1.640
Owned Owned
Unknown

Showing 1 to 15 of 68 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days